<!DOCTYPE html>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>animation</title>
	<link rel="stylesheet" href="main.css">
</head>
<body>
<div class="ipi-page">
	<div class="pi-section">
		<div class="pi-content">
			<!-- table 4 -->
			<h3 class="table-heading">Table 4: Change in Fasting Triglycerides in the 6-Week, Placebo-Controlled, Fixed-Dose MDD Trials</h3>
			<div class="table-holder table4-holder ">
				<h4 class="table-small-note"><i>Proportion of Patients with Shifts Baseline to Post-Baseline</i></h4>
				<div class="col-wrap">
					<div class="table-left-col">
						<table class="table table4">
							<thead>
								<tr>
									<td>&nbsp;</td>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td><b>Triglycerides <br> <i>Normal to High</i></b> <br> (&lt;150 mg/dL <br>to ≥200 and <br>&lt;500 mg/dL)</td>
								</tr>
								<tr>
									<td><b><i>Normal/Borderline <br>to Very High</i></b> <br>(&lt;200 mg/dL to ≥500 mg/dL)</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="table-holder">
						<div class="table-right-col responsive-table">
							<table class="table table4">
								<thead>
									<tr>
										<td>Placebo</td>
										<td>1 mg/day</td>
										<td>2 mg/day</td>
										<td>3 mg/day</td>
									</tr>
								</thead>
								<tbody>
									<tr>
										<td>6% <br>(15/257)*</td>
										<td>5% <br>(7/145)*</td>
										<td>13% <br> (15/115)*</td>
										<td>9% <br>(13/150)*</td>
									</tr>
									<tr>
										<td>0% <br>(0/309)*</td>
										<td>0% <br>(0/177)*</td>
										<td>0.7% <br>(1/143)*</td>
										<td>0% <br>(0/179)*</td>
									</tr>
								</tbody>
							</table>
						</div>
					</div>
				</div>
			</div>
			<p class="table-note">denotes n/N where N=the total number of subjects who had a measurement at baseline and at least one post-baseline result. <br>n=the number of subjects with shift.</p>
			<div class="text-holder">
				<p>In the long-term, open-label depression studies, shifts in baseline fasting cholesterol from normal to high were reported in 9% (total cholesterol), 3% (LDL cholesterol), and shifts in baseline from normal to low were reported in 14% (HDL cholesterol) of patients taking REXULTI. Of patients with normal baseline triglycerides, 17% experienced shifts to high, and 0.2% experienced shifts to very high. Combined, 0.6% of subjects with normal or borderline fasting triglycerides experienced shifts to very high fasting triglycerides during the long-term depression studies.</p>
			</div>
			<div class="text-holder">
				<h3>Schizophrenia</h3>
				<p>In the 6-week, placebo-controlled, fixed-dose clinical trials in patients with schizophrenia, changes in fasting total cholesterol, LDL cholesterol, and HDL cholesterol were similar in REXULTI- and placebo-treated patients. Table 5 shows the proportions of patients with changes in fasting triglycerides.</p>
			</div>
			<!-- table 5 -->
	
			<h3 class="table-heading">Table 5: Change in Fasting Triglycerides in the 6-Week, Placebo-Controlled, Fixed-Dose Schizophrenia Trials</h3>
			<div class="table-holder table4-holder ">
				<h4 class="table-small-note"><i>Proportion of Patients with Shifts Baseline to Post-Baseline</i></h4>
				<div class="col-wrap">
					<div class="table-left-col">
						<table class="table table4">
							<thead>
								<tr>
									<td>&nbsp;</td>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td><b>Triglycerides <br> <i>Normal to High</i></b> <br> (&lt;150 mg/dL <br>to ≥200 and <br> &lt;500 mg/dL)</td>
								</tr>
								<tr>
									<td><b><i>Normal/Borderline <br>to Very High</i></b> <br>(&lt;200 mg/dL to ≥500 mg/dL)</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="table-holder">
						<div class="table-right-col responsive-table">
							<table class="table table4">
								<thead>
									<tr>
										<td>Placebo</td>
										<td>1 mg/day</td>
										<td>2 mg/day</td>
										<td>4 mg/day</td>
									</tr>
								</thead>
								<tbody>
									<tr>
										<td>6% <br>(15/253)*</td>
										<td>10% <br>(7/72)*</td>
										<td>8% <br> (19/232)*</td>
										<td>10% <br>(22/226)*</td>
									</tr>
									<tr>
										<td>0% <br>(0/303)*</td>
										<td>0% <br>(0/94)*</td>
										<td>0% <br>(0/283)*</td>
										<td>0.4% <br>(1/283)*</td>
									</tr>
								</tbody>
							</table>
						</div>
					</div>
				</div>
			</div>
			<p class="table-note">denotes n/N where N=the total number of subjects who had a measurement at baseline and at least one post-baseline result. <br>n=the number of subjects with shift.</p>
			<div class="text-holder">
				<p>In the long-term, open-label schizophrenia studies, shifts in baseline fasting cholesterol from normal to high were reported in 6% (total cholesterol), 2% (LDL cholesterol), and shifts in baseline from normal to low were reported in 17% (HDL cholesterol) of patients taking REXULTI. Of patients with normal baseline triglycerides, 13% experienced shifts to high, and 0.4% experienced shifts to very high triglycerides. Combined, 0.6% of subjects with normal or borderline fasting triglycerides experienced shifts to very high fasting triglycerides during the long-term schizophrenia studies.</p>
			</div>
			<div class="text-holder">
				<h3 class="underline"><i>Weight Gain</i></h3>
				<p>Weight gain has been observed in patients treated with atypical antipsychotics. Clinical monitoring of weight is recommended.</p>
			</div>
			<div class="text-holder">
				<h3>Major Depressive Disorder</h3>
				<p>Table 6 shows weight gain data at last visit and percentage of adult patients with ≥7% increase in body weight at endpoint from the 6-week, placebo-controlled, fixed-dose clinical studies in patients with MDD.</p>
			</div>
		</div>
	</div>
</div>
	<script src="jquery-2.1.4.js"></script>
	<script src="main.js"></script>
	<script src="pi.js"></script>
</body>
</html>